Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Head-to-head comparison of six botulinum toxin type A products for glabellar frown lines
NL-OMON58979Phase 4Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of botulinum toxin type A in glabellar furrowing (6 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Time until loss of treatment effect. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
glabellar furrowing
Beyond the preview
Go deeper on NL-OMON58979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58979.